[Serum levels and clinical evaluation of CA 19-9 in various diseases].
We evaluated the clinical significance of serum CA 19-9 in various cancers, benign diseases and healthy controls. The percentage of positive cases for CA 19-9 (higher than 37 U/ml) was 83% in pancreas cancer, 78% in biliary tract cancer and 75% in urinary tract cancer. Benign diseases showed a low frequency of positive cases for CA 19-9, and their serum levels of CA 19-9 were low. Benign diseases with high serum levels of CA 19-9 were rarely seen, but they were easy to differentiate from malignant tumors by simultaneous examination of other tumor markers. In cancer patients with high serum levels of CA 19-9, CA 19-9 showed a weak positive correlation to CEA and ferritin.
Toyama
K
K
Noto
M
M
Sakaguchi
T
T
Adachi
K
K
Mitomi
H
H
Okada
N
N
Ootaka
H
H
Nakazawa
H
H
Hara
E
E
D000951:Antigens, Neoplasm / Q000032:analysis*; D000954:Antigens, Surface / Q000032:analysis*; D015295:Antigens, Tumor-Associated, Carbohydrate; D002272:Carcinoembryonic Antigen / Q000032:analysis; D002769:Cholelithiasis / Q000276:immunology; D000939:Epitopes / Q000032:analysis*; D005260:Female; D005293:Ferritins / Q000097:blood; D006801:Humans; D008107:Liver Diseases / Q000276:immunology; D008297:Male; D009369:Neoplasms / Q000276:immunology*; D001613:beta 2-Microglobulin / Q000032:analysis
D000951:Antigens, Neoplasm; D000954:Antigens, Surface; D015295:Antigens, Tumor-Associated, Carbohydrate; D002272:Carcinoembryonic Antigen; D000939:Epitopes; D001613:beta 2-Microglobulin; D005293:Ferritins